GO
Loading...

Bristol-Myers Squibb Co

More

  • Final Glance: Pharmaceuticals companies Friday, 20 Mar 2015 | 8:00 PM ET

    Baxter International Inc. rose$. 20 or. 3 percent, to $68.18. Bristol-Myers Squibb Co. fell$. 56 or. 8 percent, to $67.76. Eli Lilly& Co. rose $1.90 or 2.6 percent, to $76.12.

  • Midday Glance: Pharmaceuticals companies Friday, 20 Mar 2015 | 1:25 PM ET

    Baxter International Inc. fell$. 03 or percent, to $67.95. Bristol-Myers Squibb Co. rose$. 11 or. 2 percent, to $68.43. Eli Lilly& Co. rose $1.35 or 1.8 percent, to $75.57.

  • Early Glance: Pharmaceuticals companies Friday, 20 Mar 2015 | 10:19 AM ET

    Baxter International Inc. rose$. 23 or. 3 percent, to $68.21. Bristol-Myers Squibb Co. rose$. 45 or. 7 percent, to $68.77. Eli Lilly& Co. rose$. 52 or. 7 percent, to $74.74.

  • Midday Glance: Pharmaceuticals companies Thursday, 19 Mar 2015 | 2:00 PM ET

    Baxter International Inc. fell$. 62 or. 9 percent, to $67.94. Bristol-Myers Squibb Co. fell$. 21 or. 3 percent, to $68.26. Eli Lilly& Co. rose$. 38 or. 5 percent, to $73.92.

  • Early Glance: Pharmaceuticals companies Thursday, 19 Mar 2015 | 10:22 AM ET

    Baxter International Inc. fell$. 38 or. 6 percent, to $68.17. Bristol-Myers Squibb Co. fell$. 13 or. 2 percent, to $68.34. Eli Lilly& Co. fell$. 58 or. 8 percent, to $72.96.

  • Midday Glance: Pharmaceuticals companies Wednesday, 18 Mar 2015 | 2:23 PM ET

    Baxter International Inc. fell$. 81 or 1.2 percent, to $67.66. Bristol-Myers Squibb Co. fell$. 46 or. 7 percent, to $67.17. Eli Lilly& Co. rose$. 41 or. 6 percent, to $71.25.

  • Early Glance: Pharmaceuticals companies Wednesday, 18 Mar 2015 | 11:37 AM ET

    Baxter International Inc. fell$. 21 or. 3 percent, to $68.26. Bristol-Myers Squibb Co. fell$. 22 or. 3 percent, to $67.40. Eli Lilly& Co. rose$. 42 or. 6 percent, to $71.26.

  • Final Glance: Pharmaceuticals companies Tuesday, 17 Mar 2015 | 6:16 PM ET

    Baxter International Inc. rose$. 04 or. 1 percent, to $68.47. Bristol-Myers Squibb Co. fell$. 41 or. 6 percent, to $67.62. Eli Lilly& Co. fell$. 23 or. 3 percent, to $70.84.

  • Midday Glance: Pharmaceuticals companies Tuesday, 17 Mar 2015 | 2:32 PM ET

    Baxter International Inc. rose$. 26 or. 4 percent, to $68.69. Bristol-Myers Squibb Co. fell$. 54 or. 8 percent, to $67.50. Eli Lilly& Co. fell$. 36 or. 5 percent, to $70.71.

  • Early Glance: Pharmaceuticals companies Tuesday, 17 Mar 2015 | 10:28 AM ET

    Baxter International Inc. fell$. 21 or. 3 percent, to $68.22. Bristol-Myers Squibb Co. fell$. 46 or. 7 percent, to $67.57. Eli Lilly& Co. fell$. 16 or. 2 percent, to $70.91.

  • March 17- Foreign exchange swings cost North American corporates $18.66 billion in revenue in the fourth quarter, according to a report by currency risk management consulting firm FiREapps. A slew of U.S. multinational companies, from DuPont to Procter& Gamble, have showed that a strong U.S. dollar hurt their earnings, and several blue-chip exporters said the...

  • Final Glance: Pharmaceuticals companies Monday, 16 Mar 2015 | 6:03 PM ET

    Baxter International Inc. rose $1.07 or 1.6 percent, to $68.43. Bristol-Myers Squibb Co. rose $1.16 or 1.7 percent, to $68.03. Eli Lilly& Co. rose $1.18 or 1.7 percent, to $71.07.

  • Midday Glance: Pharmaceuticals companies Monday, 16 Mar 2015 | 1:19 PM ET

    Baxter International Inc. rose$. 74 or 1.1 percent, to $68.10. Bristol-Myers Squibb Co. rose $1.03 or 1.5 percent, to $67.90. Eli Lilly& Co. rose $1.34 or 1.9 percent, to $71.23.

  • Early Glance: Pharmaceuticals companies Monday, 16 Mar 2015 | 10:34 AM ET

    Baxter International Inc. rose$. 93 or 1.4 percent, to $68.29. Bristol-Myers Squibb Co. rose$. 87 or 1.3 percent, to $67.74. Eli Lilly& Co. rose $1.14 or 1.6 percent, to $71.03.

  • LONDON, March 14- Long-term use of AstraZeneca's drug Brilinta can cut the risk of death, another heart attack or stroke in patients with a history of past attacks by 16 percent, a keenly awaited clinical trial showed on Saturday. The finding may boost sales of the blood-thinner, which AstraZeneca is relying on to drive growth, although doctors must balance its...

  • Nikkei edges up, BOJ's ETF buying helps sentiment Wednesday, 4 Mar 2015 | 9:28 PM ET

    *Rakuten falls after Goldman cuts rating. TOKYO, March 5- Japan's Nikkei share average edged up on Thursday after the central bank bought more exchange-traded funds, but gains were limited by investor caution ahead of U.S. jobs data on Friday. Ono Pharmaceutical Co, which co-develops cancer treatment drug Opdivo with Bristol Myers Squibb, jumped 8 percent after...

  • *Markit, ISM services show modest growth. *Healthcare stocks rise after Supreme Court oral argument. The market had a terrific February, "said David Katz, chief investment officer at Matrix Asset Advisors, in New York.

  • LONDON, March 4- The idea of using vaccines to fight cancer has received a shot in the arm from a $1 billion deal between Bristol-Myers Squibb and Bavarian Nordic. Unfortunately, they have run into problems in practice, leading to a series of failures with experimental products such as Merck KGaA's Stimuvax and GlaxoSmithKline's MAGE-A3. The idea of combining...

  • COPENHAGEN, March 4- Bavarian Nordic has struck a prostate cancer drug deal with Bristol-Myers Squibb that could be worth $1 billion should its trials, part of a new field in cancer treatment, be successful. The jump added over $260 million to its market value of $880 million. In that trial, patients were treated with Prostvac in addition to escalating doses of...

  • COPENHAGEN, March 4- Shares in Bavarian Nordic leapt as much as 39 percent on Wednesday after the Danish biotech company announced a prostate cancer drug deal with Bristol-Myers Squibb that could be worth at least $1 billion. Under the deal, Bavarian Nordic could receive up to $975 million, including $60 million upfront, if it passes trials and sales milestones,...